Garver D L, Dekirmenjian H, Davis J M, Casper R, Ericksen S
Am J Psychiatry. 1977 Mar;134(3):304-7. doi: 10.1176/ajp.134.3.304.
The authors studied neuroleptic concentration-therapeutic response curves for butaperazine (BPZ), a piperazine phenothiazine, in 10 schizophrenic patients during the first 12 days of treatment. BPZ bound to red blood cells (RBC) was more strongly correlated with therapeutic response than was plasma BPZ. RBC BPZ concentrations could be used to define a "therapeutic window", an optimun concentration for therapeutic response, above and below which favorable response diminishes. The authors emphasize the preliminary nature of the data but suggest that levels of RBC-bound neuroleptic may provide an important guide for dosage regulation in schizophrenic patients.
作者研究了哌嗪吩噻嗪类药物丁酰拉嗪(BPZ)在10例精神分裂症患者治疗的前12天内的抗精神病药物浓度-治疗反应曲线。与血浆BPZ相比,与红细胞(RBC)结合的BPZ与治疗反应的相关性更强。RBC BPZ浓度可用于定义一个“治疗窗”,即治疗反应的最佳浓度,高于或低于此浓度,良好反应会减弱。作者强调这些数据的初步性质,但建议红细胞结合的抗精神病药物水平可能为精神分裂症患者的剂量调节提供重要指导。